Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 10, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

September 10, 2018

Conditions
Insulin Sensitivity
Interventions
DRUG

Maltodextrin

Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.

DRUG

Synbiotic

Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.

DRUG

Sevelamer

Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks

Trial Locations (1)

78229

Audie L. Murphy VA Hospital, STVHCS, San Antonio

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02127125 - Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2) | Biotech Hunter | Biotech Hunter